Peter BrÃ¸nnum Nielsen

List of Publications by Year
in descending order

92 papers	2,551 citations	236612 25 h-index	197535 49 g-index
92 all docs	92 docs citations	92 times ranked	3324 citing authors

#	Article	IF	Citations
1	Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ, The, 2016, 353, i3189.	3.0	351
2	Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ: British Medical Journal, 2017, 356, j510.	2.4	275
3	Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding. Circulation, 2015, 132, 517-525.	1.6	225
4	Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation. Circulation, 2018, 137, 832-840.	1.6	158
5	Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. Thrombosis and Haemostasis, 2015, 114, 826-834.	1.8	100
6	Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clinical Research in Cardiology, 2015, 104, 418-429.	1.5	87
7	Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. Neurology, 2017, 89, 687-696.	1.5	79
8	Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation. JAMA Internal Medicine, 2017, 177, 563.	2.6	75
9	Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. Scientific Reports, 2016, 6, 27410.	1.6	67
10	Risk of Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study. American Journal of Medicine, 2018, 131, 1067-1074.e4.	0.6	55
11	Non-Vitamin K Antagonist Oral Anticoagulants and the Treatment of Venous Thromboembolism in Cancer Patients: A Semi Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. PLoS ONE, 2014, 9, e114445.	1.1	54
12	Atrial flutter and thromboembolic risk: a systematic review. Heart, 2015, 101, 1446-1455.	1.2	54
13	Î²-Blockers in Atrial Fibrillation Patients With or Without Heart Failure. Circulation: Heart Failure, 2016, 9, e002597.	1.6	49
14	The risks of risk scores for stroke risk assessment in atrial fibrillation. Thrombosis and Haemostasis, 2015, 113, 1170-1173.	1.8	48
15	The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants. American Journal of Medicine, 2018, 131, 574.e13-574.e27.	0.6	46
16	Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor. JAMA Cardiology, 2017, 2, 872.	3.0	44
17	Intracranial Hemorrhage and Subsequent Ischemic Stroke in Patients With Atrial Fibrillation. Chest, 2015, 147, 1651-1658.	0.4	43
18	Glycemic Status and Thromboembolic Risk in Patients With Atrial Fibrillation and Type 2 Diabetes Mellitus. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007030.	2.1	39

#	Article	IF	Citations
19	Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study. Lancet Haematology,the, 2017, 4, e237-e244.	2.2	36
20	The Value of the European Society of Cardiology Guidelines for Refining Stroke Risk Stratification in Patients With Atrial Fibrillation Categorized as Low Risk Using the Anticoagulation and Risk Factors in Atrial Fibrillation Stroke Score. Chest, 2014, 146, 1337-1346.	0.4	34
21	Nonâ€“Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage. Stroke, 2019, 50, 939-946.	1.0	34
22	Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA ₂ DS ₂) Tj ETQq0 0 0 rgBT /Overlock 10	1.6	33
23	Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA₂DS₂-VASc score. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 37-41.	1.4	32
24	Associations between socioeconomic status, atrial fibrillation, and outcomes: a systematic review. Expert Review of Cardiovascular Therapy, 2018, 16, 857-873.	0.6	27
25	Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating â€˜valvular heart diseaseâ€™ in a nationwide cohort study. Europace, 2019, 21, 33-40.	0.7	27
26	Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: A systematic review and meta-analysis. International Journal of Cardiology, 2018, 261, 84-91.	0.8	26
27	Female Sex as a Risk Modifier for Stroke Risk in Atrial Fibrillation: Using CHA2DS2-VASc versus CHA2DS2-VA for Stroke Risk Stratification in Atrial Fibrillation: A Note of Caution. Thrombosis and Haemostasis, 2020, 120, 894-898.	1.8	26
28	Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy. Blood Advances, 2022, 6, 2967-2976.	2.5	23
29	Sex Differences in Treatment Quality of Self-Managed Oral Anticoagulant Therapy: 6,900 Patient-Years of Follow-Up. PLoS ONE, 2014, 9, e113627.	1.1	22
30	Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: A Danish nationwide cohort study. International Journal of Cardiology, 2018, 268, 137-142.	0.8	22
31	Evaluation of the C2HEST Risk Score as a Possible Opportunistic Screening Tool for Incident Atrial Fibrillation in a Healthy Population (From a Nationwide Danish Cohort Study). American Journal of Cardiology, 2020, 125, 48-54.	0.7	20
32	Atrial Fibrillation Patients Categorized as â€œNot for Anticoagulationâ€•According to the 2014 Canadian Cardiovascular Society Algorithm Are Not â€œLow Riskâ€• Canadian Journal of Cardiology, 2015, 31, 24-28.	0.8	17
33	Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism. American Journal of Medicine, 2018, 131, 787-794.e4.	0.6	17
34	Albuminuria and Risk of Cardiovascular Events and Mortality in a General Population of Patients with Type 2 Diabetes Without Cardiovascular Disease: A Danish Cohort Study. American Journal of Medicine, 2020, 133, e269-e279.	0.6	17
35	Sex differences in risk of incident venous thromboembolism in heart failure patients. Clinical Research in Cardiology, 2019, 108, 101-109.	1.5	15
36	Effectiveness and safety of self-managed oral anticoagulant therapy compared with direct oral anticoagulants in patients with atrial fibrillation. Scientific Reports, 2018, 8, 15805.	1.6	14

#	Article	IF	Citations
37	Risk of recurrence and bleeding in patients with cancerâ€associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study. Cancer Medicine, 2019, 8, 1044-1053.	1.3	14
38	Thromboembolism and bleeding complications in anticoagulated patients with atrial fibrillation and native aortic or mitral valvular heart disease: a descriptive nationwide cohort study. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f101-f110.	1.4	14
39	Adding Rigor to Stroke Rate Investigations in Patients With Atrial Fibrillation. Circulation, 2017, 135, 220-223.	1.6	13
40	Development of Sex-Stratified Prediction Models for Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study. Thrombosis and Haemostasis, 2020, 120, 805-814.	1.8	13
41	Understanding the Value of Real-World Evidence: Focus on Stroke Prevention in Atrial Fibrillation with Rivaroxaban. Thrombosis and Haemostasis, 2018, 118, S45-S60.	1.8	12
42	Temporal Changes in Secondary Prevention and Cardiovascular Outcomes After Revascularization for Peripheral Arterial Disease in Denmark. Circulation, 2021, 143, 907-920.	1.6	12
43	Self-Management of Anticoagulant Therapy in Mechanical Heart Valve Patients: A Matched Cohort Study. Annals of Thoracic Surgery, 2016, 101, 1494-1499.	0.7	11
44	Stroke Risk Stratification: CHA2DS2-VA or CHA2DS2-VASc?. Heart Lung and Circulation, 2019, 28, e14-e15.	0.2	10
45	Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial. European Journal of Vascular and Endovascular Surgery, 2022, 63, 285-294.	0.8	10
46	Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy. JAMA Network Open, 2022, 5, e2213945.	2.8	10
47	Improvement of anticoagulant treatment using a dynamic decision support algorithm. Thrombosis Research, 2014, 133, 375-379.	0.8	9
48	Recalibration of the HAS-BLED Score. Chest, 2016, 149, 311-314.	0.4	9
49	Self-managed oral anticoagulant therapy: a call for implementation. Expert Review of Cardiovascular Therapy, 2016, 14, 255-257.	0.6	9
50	Incidence and prognostic factors for recurrence of intracerebral hemorrhage in patients with and without atrial fibrillation: A cohort study. Thrombosis Research, 2020, 191, 1-8.	0.8	9
51	Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants. Cancer Medicine, 2021, 10, 4405-4414.	1.3	8
52	Temporal trends in abdominal aortic aneurysmal disease: a nationwide cohort study on cardiovascular morbidity and medical cardioprotective therapy. European Journal of Preventive Cardiology, 2022, 29, 1957-1964.	0.8	8
53	Risk Stratification for Ischemic Cerebrovascular Events and Mortality among Intracerebral Hemorrhage Patients with and without Atrial Fibrillation: A Nationwide Cohort Study. Cerebrovascular Diseases, 2019, 48, 236-243.	0.8	6
54	Cancer-associated venous thromboembolism and the non-vitamin K antagonist oral anticoagulants: a review of clinical outcomes and patient perspectives. Expert Review of Cardiovascular Therapy, 2020, 18, 791-800.	0.6	6

#	Article	IF	Citations
55	Thromboembolic and bleeding outcomes in patients with atrial fibrillation and valvular heart disease: A descriptive nationwide cohort study. International Journal of Clinical Practice, 2020, 74, e13589.	0.8	6
56	Oral antiâ€coagulant treatment patterns in atrial fibrillation patients diagnosed with cancer: A Danish nationwide cohort study. British Journal of Haematology, 2022, 197, 223-231.	1.2	6
57	Predictors of Not Initiating Anticoagulation After Incident Venous Thromboembolism: A Danish Nationwide Cohort Study. American Journal of Medicine, 2020, 133, 463-472.e5.	0.6	5
58	Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 31-39.	1.4	5
59	Effectiveness and Safety of NOAC Versus Warfarin in Patients With Atrial Fibrillation and Aortic Stenosis. Journal of the American Heart Association, 2021, 10, e022628.	1.6	5
60	Risk of Cerebrovascular Events in Intracerebral Hemorrhage Survivors With Atrial Fibrillation: A Nationwide Cohort Study. Stroke, 2022, 53, 2559-2568.	1.0	5
61	Monitoring of anticoagulant therapy applying a dynamic statistical model. Computer Methods and Programs in Biomedicine, 2013, 110, 380-388.	2.6	4
62	A two-sided evaluation of benefit and harm from antithrombotic treatment in atrial fibrillation: Balancing clinical application and statistical methodology. Thrombosis and Haemostasis, 2016, 116, 405-406.	1.8	4
63	Misconceptions on Interpretation of Risk Prediction Tools in Atrial Fibrillation. American Journal of Medicine, 2016, 129, e31.	0.6	4
64	Searching for High-Risk Venous Thromboembolism Patients Using Risk Scores: Adding to the Heap or Closing a Gap?. Thrombosis and Haemostasis, 2018, 118, 1686-1687.	1.8	4
65	First trimester anticoagulant exposure and adverse pregnancy outcomes in women with preconception venous thromboembolism: a nationwide cohort study. American Journal of Medicine, 2021, , .	0.6	4
66	Disparities in oral anticoagulation initiation in patients with schizophrenia and atrial fibrillation: A nationwide cohort study. British Journal of Clinical Pharmacology, 2022, 88, 3847-3855.	1.1	4
67	Premature atrial complexes in an ischemic stroke population and risk of recurrent stroke: a systematic review. Expert Review of Cardiovascular Therapy, 2017, 15, 447-455.	0.6	3
68	Extended oral anticoagulation after incident venous thromboembolism â€“ a paradigm shift?. Expert Review of Cardiovascular Therapy, 2020, 18, 201-208.	0.6	3
69	Comparative effectiveness and safety of edoxaban versus warfarin in patients with atrial fibrillation: A nationwide cohort study. International Journal of Stroke, 2022, 17, 536-544.	2.9	3
70	Letter by Nielsen and Johnsen Regarding Article, â€œOptimal Timing of Anticoagulant Treatment After Intracerebral Hemorrhage in Patients With Atrial Fibrillationâ€. Stroke, 2017, 48, e115-e115.	1.0	2
71	Characteristics of patients receiving extended treatment after incident venous thromboembolism. Basic and Clinical Pharmacology and Toxicology, 2021, 129, 332-342.	1.2	2
72	Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy, 2015, 13, 1155-1163.	0.6	1

#	Article	IF	Citations
73	Anticoagulant treatment of cancerâ€associated venous thromboembolism: Interpreting realâ€world data with caution. American Journal of Hematology, 2018, 93, E224-E225.	2.0	1
74	Stroke risk in female patients with atrial fibrillation: Relationship to current guideline recommendations. Trends in Cardiovascular Medicine, 2019, 29, 150-152.	2.3	1
75	Correspondence: Current opinion of the ESC Working Group on Cardiovascular Pharmacotherapy and ESC Council on Stroke. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 265-266.	1.4	1
76	How to optimize the value of administrative venous thromboembolism codes. Thrombosis Research, 2020, 194, 195-196.	0.8	1
77	Should we make the risk stratification process more complex in patients with atrial fibrillation?. Europace, 2021, 23, 978-978.	0.7	1
78	Letter by Nielsen and SÃ¸gaard Regarding Article, â€œRivaroxaban Versus Apixaban for Stroke Prevention in Atrial Fibrillation: An Instrumental Variable Analysis of a Nationwide Cohortâ€• Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006889.	0.9	1
79	Thromboembolic Risk in Nonanticoagulated Patients With Atrial Fibrillation and Valvular Heart Disease. JACC: Clinical Electrophysiology, 2020, 6, 1672-1682.	1.3	1
80	Comparison of Atrial Fibrillation Guidelines. Journal of General Internal Medicine, 2015, 30, 1404-1404.	1.3	0
81	Pharmacoepidemiological comparisons between acenocoumarol and dabigatran: interpretation of data reflecting clinical practice. Europace, 2016, 18, 1283-1284.	0.7	0
82	Stroke and mortality after atrial fibrillationâ€”a global struggle. Lancet, The, 2016, 388, 1131-1132.	6.3	0
83	Response by Nielsen and Lip to Letter Regarding Article, â€œShould Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA 2 DS 2 -VASc Score 1 in Men, 2 in Women) Be Anticoagulated? Yes: Even 1 Stroke Risk Factor Confers a Real Risk of Strokeâ€• Circulation, 2016, 134, e389-e390.	1.6	0
84	Letter by Nielsen et al Regarding Article, â€œIschemic Stroke Risk in Patients With Atrial Fibrillation and CHA 2 DS 2 -VASc Score of 1: Systematic Review and Meta-Analysisâ€• Stroke, 2016, 47, e193.	1.0	0
85	Response. Chest, 2016, 149, 1590-1591.	0.4	0
86	All Types of Hemorrhagic Stroke Are Not Created Equallyâ€”Reply. JAMA Internal Medicine, 2017, 177, 1399.	2.6	0
87	Response by Overvad et al to Letter Regarding Article, â€œFemale Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA 2 DS 2 -VA Score Rather Than CHA 2 DS 2 -VASc?â€• Circulation, 2018, 138, 443-444.	1.6	0
88	Causal Inference From Real-World Data. Journal of the American College of Cardiology, 2018, 72, 486-488.	1.2	0
89	Etiological Research Using Observational Data, and Net Clinical Benefit. Simplicity and Practicality Matter. American Journal of Medicine, 2019, 132, 671-672.	0.6	0
90	Intracerebral Hemorrhage and Exposure to Antithrombotic Drugs. JAMA Network Open, 2021, 4, e219175.	2.8	0

#	Article	IF	Citations
91	Navigating the Passage for Better Understanding and Prognosis for Acute Limb Ischemia After Lower-Extremity Revascularization. Circulation, 2021, 144, 1842-1844.	1.6	0
92	Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial. Journal of Vascular Surgery, 2022, 75, 1119-1120.	0.6	0